Daily Stock List
Legend Oil and Gas, Ltd. (LOGL)
SmarTrend Newsletters and Trade of the Week reported previously on Legend Oil and Gas, Ltd. (LOGL), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Legend Oil and Gas, Ltd. is an oil and gas exploration, development and production company whose shares trade on the OTCQB. The Company's focus is to acquire producing and non-producing oil and gas right interests and develop oil and gas properties that they own or have a leasehold interest in. In addition, they anticipate pursuing the acquisition of leaseholds and sites within other geographic areas that meet their general investment guidelines and targets. Legend Oil and Gas is based in Seattle, Washington.
The Company's oil and gas property interests are in Western Canada (in Berwyn, Medicine River, Boundary Lake, and Wildmere in Alberta, and Clarke Lake and Inga in British Columbia). Additionally, they are in the U.S. (in the Piqua region of the State of Kansas).
Concerning the Piqua Project, it is in Woodson County, Kansas. Its size is 1,040 acres of net mineral leases. Production is 18 BOPD, and the number of active wells is 44. The well type is oil and water injection and the Company's freehold royalty is 12.5 percent. Legend intends to concentrate on their Kansas asset base this year.
Pertaining to their Canadian Projects, the Canadian assets acquired by Legend Oil and Gas are administered within their wholly owned subsidiary Legend Energy Canada Ltd. (LECL). These assets contain oil and gas properties presently producing close to200 BOE/d. The properties contain a mix of 37 percent oil and natural gas liquid production, and 63 percent gas production. The majority of the properties are in Alberta. Close to 41 percent of the total sales are taken from British Columbia, located directly west of Alberta.
Total Canadian production is contained within 9 production entities. Moreover, 82 percent of the total is contained within the Berwyn, Medicine River and Wildmere properties in Alberta and Clarke Lake in British Columbia. The majority of Legend's operational duties are outsourced to consultants and independent contractors. This includes for drilling, maintaining and operating their wells.
This past March, Legend Oil and Gas announced that they received the year-end values for their oil and gas production and reserves from their third party engineering firms. The asset evaluation process demonstrated the value addition that has been obtained from the drilling performed in Kansas during 2012. Proven Developed Producing reserve values have increased 40.1 percent with Proven Un-Developed values rising 15.4 percent or an overall Total Proven value increase of 22.9 percent.
Legend Oil and Gas, Ltd. (LOGL), closed Thursday's trading session at $0.052, down 1.89%, on 100,301 volume with 13 trades. The average volume for the last 60 days is 76,251 and the stock's 52-week low/high is $0.03/$0.30.
Hansen Medical, Inc. (HNSN)
Wall Street Resources and The Street reported earlier on Hansen Medical, Inc. (HNSN), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
Listed on the Nasdaq Global Market, Hansen Medical, Inc. is the worldwide leader in intravascular robotics. They develop products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Sensei® Robotic Catheter System and Artisan® Control Catheter used in electrophysiology procedures were their first advanced medical robotics. The Magellan™ Robotic System and Magellan™ Robotic Catheter are the next generation of intravascular robotics technology designed for peripheral vascular interventions. Hansen Medical has their headquarters in Mountain View, California.
In the European Union, Hansen's Sensei® X Robotic Catheter System and Artisan Control Catheter are cleared for use during electrophysiology (EP) procedures. This includes guiding catheters in the treatment of atrial fibrillation (AF). The Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map as well as patient electrocardiogram data.
In the United States, their Sensei X Robotic Catheter System and Artisan Control Catheter were cleared by the U.S. Food and Drug Administration (FDA) for manipulation and control of certain mapping catheters in EP procedures. In the U.S, the Sensei System is not approved for use in guiding ablation procedures. This use is still experimental. The U.S. product labeling for that reason provides that the safety and effectiveness of the Sensei X System and Artisan Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established.
At the end of April, Hansen Medical announced the results from a recently published pre-clinical study describing potential benefits of the Company's robotic technology for the treatment of carotid arteries. The study results appeared in the Journal of Cardiovascular Surgery, December 2012.
Concerning some recent business highlights, the Company shipped four systems (3 Magellan™ Systems and 1 Sensei® System) in the first quarter. Hansen is anticipating the commercialization of 14 to 17 Magellan and Sensei Systems in 2013. Nine Magellan systems are installed and in clinical use at March 31, 2013. Approximately 150 vascular cases have now been performed to date using the Magellan System. This demonstrates extensive clinical applications in the peripheral vasculature.
Hansen Medical, Inc. (HNSN), closed Thursday's trading session at $1.60, up 1.27%, on 343,491 volume with 1,541 trades. The average volume for the last 60 days is 286,634 and the stock's 52-week low/high is $1.42/$2.84.
Labrador Iron Mines Holdings Ltd. (LIM.TO)
Vantage Wire and Super Stock Picker reported earlier on Labrador Iron Mines Holdings Ltd. (LIM.TO), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.
Based in Toronto, Ontario, Labrador Iron Mines Holdings Ltd. is Canada's newest iron ore producer. The Company has a portfolio of direct shipping (DSO) iron ore operations and projects located in the productive Labrador Trough. At present, Labrador Iron Mines is the only independently owned Canadian iron ore producer listed on the Toronto Stock Exchange. The Company also has offices in Schefferville, Quebec, and in St. John's, Labrador City, and Goose Bay Newfoundland and Labrador.
The Company's mine operations involve the extraction of iron ore by developing open pit mines, starting with the James Mine. The James Mine is connected by a direct rail link to the Port of Sept-Îles, Québec. The project also benefits from established infrastructure including the town, airport, and hydropower and railway service. Starting with the James Mine and leading to the development of the expanding Houston flagship project, Labrador Iron Mines has a plan to increase production towards 5 million tonnes annually from a portfolio of iron ore deposits in Labrador and Quebec, all within 50 kilometers of the town of Schefferville.
Initial production started at the James Mine in June of 2011, with the sale of 386,000 dry tonnes of iron ore recorded in the first start-up year. The first full production season began in April 2012; Labrador Iron Mines sold ten shipments totaling approximately 1.6 million dry tonnes of iron ore. The tenth shipment sold at the end of November 2012 and contained 103,000 dry tonnes of iron ore.
The Company began their third year of direct shipping iron ore production from their Schefferville area iron ore mines in Western Labrador last month. They are targeting production of 1.75 to 2.0 million tonnes of sinter fines and lump this year. The expectation is that the first Capesize shipment of 2013 will be loaded around the end of this month.
This week, Labrador Iron Mines Holdings reported that they entered into a new iron ore sales agreement with the Iron Ore Company of Canada (IOC). This is for the sale of all of Labrador Iron Mines' iron ore production for the next two calendar years - 2013 and 2014. Simultaneously, the Company announced that they entered into an off-take financing agreement with RB Metalloyd Ltd. (RBM) under which Labrador Iron Mines will receive an advance payment of US$35 million to be credited against future sales of a minimum of 3.5 million tonnes of iron ore during 2013 and 2014. RBM is a leading global commodity trading house.
Labrador Iron Mines Holdings Ltd. (LIM.TO), closed Thursday's trading session at $0.57, down 5.00%, on 483,378 volume. The stock's 52-week low/high is $0.54/$3.75.
Unilava Corp. (UNLA)
Value Penny Stocks, Stock Analyzer, PennyStocks24, FOX Penny Stocks, Winning Penny Stock Picks, WePickPennyStocks, Super Nova Stock Picks, Super Hot Penny Stocks, Penny Stock Pick Report, Penny Stock Pick Alert, PennyStockMoneyTrain, and Liquid Tycoon reported recently on Unilava Corp. (UNLA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
With their subsidiary brands, Unilava Corp. is a provider of diversified communication services across multiple devices and software platforms. Unilava provides feature-rich technology that offers flexibility, mobility and user-friendly applications. The Company has licensing to provide long distance services in 41 States and local phone services in 11 States. Their services sell on the web and in retail stores across the nation. Unilava lists on the OTCQB; the Company has their headquarters in San Francisco, California. Unilava has regional offices in Chicago, Seoul, Hong Kong, and Beijing.
Unilava's subsidiaries mainly conduct the Company's operations. The Company provides an array of communications services, products, and equipment that address the needs of small and medium sized enterprise businesses and consumers under the Unilava corporate brand. This includes their retail brands consisting of Telava™, Countryconnect™, Telava™ Mobile, Local Area Yellow Pages, Ttoore, Counia, and Nationwide Roadside Assistance.
The Company groups their operating subsidiaries. Wireless subsidiaries provide wireless voice and data communications services across the U.S. and, through agreements, in many foreign countries. Wireline subsidiaries provide primarily landline voice and data communication services, high-speed broadband, as well as voice services.
Advertising solutions subsidiaries publish Local Area Yellow Pages directories and sell directory advertising and Internet-based advertising and local search. Other subsidiaries provide results from all corporate and other operations. Unilava owns 40 carrier-grade microwave towers across the U.S offering collocation services and wireless broadband connectivity.
Unilava offers mobile and high-definition IP-hosted voice services to residential, small and medium enterprises via their carrier-grade microwave wireless broadband infrastructure and broadband Internet access partners. They deliver small businesses a total and integrated portfolio of fee-based online and mobile advertising and web services.
The services and products that the Company offers differ by particular market. They include wireless communications, local exchange services, long-distance services, data/broadband and Internet services, video services telecommunications equipment, wholesale services and directory advertising and publishing.
Unilava Corp. (UNLA), closed Thursday's trading session at $0.0185, up 236.36%, on 13,405,345 volume with 588 trades. The average volume for the last 60 days is 440,426 and the stock's 52-week low/high is $0.0015/$0.045.
Mikros Systems Corp. (MKRS)
PennyStocks24, AwesomeStocks, TerrificPennyStocks, PennyStockProphet, Penny Stock General, Penny Pick Finders, SquawkBoxStocks, Chatter Box Stocks, OTCPicks, SecretStockPromo, Stock Twiter, and OTCEquity reported recently on Mikros Systems Corp. (MKRS). Stock Shock and Awe, Buzz Stocks, Planet Penny Stocks, Mad Money Picks, Fast Money Alerts, StockOnion, and VIP Penny Stocks also reported recently, and we highlight the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Princeton, New Jersey, Mikros Systems Corp. is an advanced technology enterprise that specializes in the research and development of electronic systems technology, principally for military applications. The Company's main business is to pursue and obtain contracts from the Department of Homeland Security, the U.S. Navy, and other governmental authorities. Founded in Albany, New York, Mikros Systems' shares trade on the OTC Markets' OTCQB.
Mikros Systems capabilities include technology management, electronic systems engineering and integration, radar systems engineering, combat/command, control, communications, computers and intelligence systems engineering, and communications engineering. Their products and services include ADEPT®. The Adaptive Diagnostic Electronic Portable Testset (ADEPT®) is an intelligent, automated, programmable electronic test tool designed to aid technical personnel in the maintenance, alignment, calibration, and error diagnosis of radar and other complex electronic systems.
ADEPT units undergo manufacture in the Mikros Largo, Florida facility. DRS Technologies performs initial build and assembly. Final assembly and testing is performed by Mikros under a $26M contract from the Naval Weapons Center in Crane, Indiana. Moreover, Mikros has their NVEA product. Network Vulnerability to Electronic Attack (NVEA) is a software simulation tool. NVEA models tactical data links in a hostile electromagnetic environment; it allows evaluation of network performance throughout a planned mission scenario.
Concerning Engineering Services, the Company's engineers are developing autonomous buoy solutions for persistent surveillance applications using wave-power technologies developed by Ocean Power Technologies. Mikros also develops and implements Information Assurance (IA) plans, and System Security Authorization and Agreements (SSAA) in accordance with Department of Defense (DoD) Security policies. Mikros engineers conduct research and development to determine the effects of radio frequency interference on wireless networks. The Company developed computer algorithms that help automate and optimize wireless network planning.
In April, Mikros Systems announced fourth quarter and year-end results for the period ending December 31, 2012. Highlights include Revenues for the fourth quarter increasing 9 percent to $2.5 million. This is in comparison to $2.3 million in the same period the year prior.
Gross profit margin for the year increased to 44 percent from 40 percent in 2011. Net income for the year was $227,109. This is versus $169,619 in 2011, which represents an increase of 34 percent. Net Cash and Cash equivalents remained stable at $1 million.
Mikros Systems Corp. (MKRS), closed Thursday's trading session at $0.095, up 35.71%, on 5,375 volume with 2 trades. The average volume for the last 60 days is 66,332 and the stock's 52-week low/high is $0.02/$0.60.
MultiCell Technologies, Inc. (MCET)
Wallstreelivechat, UltimatePennyStock, Investors Online Bell, and Bird Gang Stocks reported earlier on MultiCell Technologies, Inc. (MCET), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company with corporate headquarters in Woonsocket, Rhode Island. The Company is developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer. Their portfolio of lead drug candidates is in different stages of discovery optimization, and preclinical and clinical development. Xenogenics Corp. is a subsidiary of MultiCell Technologies. MultiCell lists on the OTCQB.
Their therapeutic development platform relies on several patented technologies. These are used to isolate, characterize and differentiate stem cells from human liver, or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling. These are also used to generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or modulate the noradrenaline-adrenaline neurotransmitter pathway.
MultiCell Technologies' portfolio of lead drug candidates includes MCT-125, MCT-465, MCT-475, and MCT-485. MCT-125 is a Phase 2 therapeutic candidate for the treatment of PMSF. It has demonstrated efficacy in a 138 patient Phase IIa clinical trial. MCT-465 is a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475 is a discovery stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers. In addition, MultiCell Technologies sells a spectrum of life science research reagents. These reagents facilitate the discovery and development of new therapies and diagnostic tests.
Today, MultiCell Technologies announced the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) that has demonstrated oncolytic and immune stimulating activity in "in vitro" models of hepatocellular carcinoma. A potential role for noncoding double stranded miRNAs such as MCT-485 in the control of tumors has recently emerged in an assortment of models with recognition of their ability to stimulate an immune response or directly affect cell death.
MultiCell Technologies, Inc. (MCET), closed Thursday's trading session at $0.0021, up 75.00%, on 272,623,753 volume with 725 trades. The average volume for the last 60 days is 35,608,029 and the stock's 52-week low/high is $0.001/$0.0067.
Columbia Laboratories, Inc. (CBRX)
SmarTrend Newsletters, FNNO Newsletters, TopStockAnalysts, and AllPennyStocks reported earlier on Columbia Laboratories, Inc. (CBRX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Columbia Laboratories, Inc. is a specialty pharmaceutical company that lists on the Nasdaq Capital Market. The Company has a successful history of developing proprietary, vaginally administered products for women's health indications. Their products use the principles of bioadhesion to achieve controlled, sustained delivery of hormones and other compounds that are difficult to administer. Columbia Laboratories has their corporate headquarters in Livingston, New Jersey.
Columbia receives sales and royalty revenues from CRINONE® (progesterone gel), marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in more than 60 foreign countries. Commercially available products using Columbia Laboratories' drug delivery technologies include this CRINONE® 8% (progesterone gel), as well as CRINONE® 4% (progesterone gel), STRIANT® (testosterone buccal system), Replens® vaginal moisturizer, and RepHresh® vaginal gel.
Each of the Company's marketed products and product candidates makes use of their bioadhesive drug delivery system (BDS) technology. The key ingredient in the BDS is polycarbophil, a non-immunogenic, hypoallergenic, bioadhesive polymer. Polycarbophil bonds to the cells of the body's mucosal surfaces upon administration. Once in place, the BDS releases the active drug in a controlled and sustained manner until it is discharged upon normal cell turnover. This occurs every 3 to 5 days for the vaginal epithelium and up to every 24 hours for the oral mucosa.
In April, Columbia Laboratories announced that they amended their license and supply agreement with Merck Serono, a division of Merck KGaA (MRK.DE), Darmstadt, Germany, for CRINONE® (progesterone gel) through May 2020. This represents an extension of five years beyond the present term, which was due to expire in May 2015.
Last week, Columbia Laboratories reported financial results for the three-month period ended March 31, 2013. Selected highlights of the first quarter include total net revenues increasing 65 percent to $6.3 million in the first quarter of 2013, versus $3.8 million in the first quarter of 2012. Operating income was $1.0 million; this is in comparison to an operating loss of $1.3 million in the first quarter of 2012. Cash, cash equivalents and short-term investments increased by $0.6 million in the quarter to $29.2 million at March 31, 2013. Columbia Laboratories reported net income of $1.2 million, or $0.01 per basic and diluted share. This is in comparison to net income of $5.0 million, or $0.06 per basic and $(0.01) per diluted share, for the first quarter of 2012.
Columbia Laboratories, Inc. (CBRX), closed Thursday's trading session at $0.6463, up 2.55%, on 372,096 volume with 571 trades. The average volume for the last 60 days is 262,069 and the stock's 52-week low/high is $0.551/$1.23.
Sprott Resource Lending Corp. (SIL.TO)
We are reporting on Sprott Resource Lending Corp. (SIL.TO) today, here at the QualityStocks Daily Newsletter.
Based in Toronto, Ontario, Sprott Resource Lending Corp. specializes in lending to resource companies on an international basis. They look to generate income from lending activities and the upside potential of bonus arrangements with borrowers typically tied to the underlying property or shares of the borrower. The Company, in essence, is a natural resource lender concentrating on providing financing to mining and oil and gas companies. Their leadership team has considerable lending experience and substantial expertise investing in the natural resource space. Sprott Resource Lending lists on the Toronto Stock Exchange.
Pursuant to a management services agreement and partnership agreement, Sprott Lending Consulting Limited Partnership (SLCLP) provides Sprott Resource Lending everyday business management and other management and administrative services. SLCLP is a wholly owned subsidiary of Sprott, Inc., the parent of Sprott Asset Management LP, a foremost Canadian independent money manager.
Last week, Sprott, Inc. (SII.TO) and Sprott Resource Lending announced that they entered into a definitive agreement whereby Sprott will acquire, by way of a court-approved plan of arrangement under the Canada Business Corporations Act (CBCA), all of the issued and outstanding common shares of Sprott Resource Lending.
Mr. Murray Sinclair, Chairman of Sprott Resource Lending's Board of Directors, said, "We are pleased to enter into this agreement with Sprott. This transaction provides our shareholders with a premium to the current share price and gives them an opportunity to participate in the growth of a larger, more diversified company with significant upside to the resource sector."
In addition, last week, Sprott Resource Lending reported their financial results for the three months ended March 31, 2013. Selected highlights include Resource loans and bonds increasing to $169 million at March 31, 2013 from $145 million at December 31, 2012. Net income in the first quarter of 2013 was $5.7 million (or $0.04 per common share). This is in comparison to $5.4 million (or $0.04 per common share) in the first quarter of 2012.
Sprott Resource Lending's overall resource loan and bond portfolio presently stands at approximately $153 million. Furthermore, the Company currently has $10 million in binding loan commitments and signed term sheets. Their pipeline of new lending opportunities continues to run greater than $100 million.
Sprott Resource Lending Corp. (SIL.TO), closed Thursday's trading session at $1.50, even for the day, on 778,541 volume. The stock's 52-week low/high is $1.23/$1.58.
Rafarma Pharmaceuticals, Inc. (RAFA)
The QualityStocks Daily Newsletter would like to spotlight Rafarma Pharmaceuticals, Inc. (RAFA). Today, Rafarma Pharmaceuticals, Inc. closed trading at $0.138, up 38.00%, on 1,670 volume with 3 trades. The stock’s average daily volume over the past 60 days is 14,889, and its 52-week low/high is $0.0501/$0.98.
Rafarma Pharmaceuticals, Inc. (RAFA) is a multiproduct pharmaceutical company specializing in the production of generic antibiotics and specialty pharmaceuticals, including its own proprietary products approved by the ministry of health. Rafarma stands as one of the most ambitious projects in recent medical history, having constructed the most technologically advanced pharmaceutical plant in Russia.
Based in Terbuny, Lipetsk region, Russia, Rafarma possesses a unique niche in the burgeoning pharmaceutical market and is poised to become a major player in the international drug industry. The company was established under the auspices of the Foundation to Support Health Care and has been approved by the Ministry of Health.
Rafarma recently received the general license for pharmaceutical products and began manufacturing three new products: Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin. Receiving the general license was one of the final steps the company needed to open its new plant in Terbuniv, and Rafarma has been named one of only four national strategic pharmaceutical suppliers to the Russian Federation.
Advances in health care science, medicine, and technology have increased the general life expectancy of Eastern European citizens steadily over the past decade. Elderly citizens, which comprise the largest portion of the pharmaceuticals market, have bolstered demand for pharmaceuticals nationwide. Rafarma is well positioned to capitalize on the expanding industry with its strong relationships and state-of-the-art production facility. Disclaimer
Rafarma Pharmaceuticals, Inc. Company Blog
Rafarma Pharmaceuticals, Inc. News:
Rafarma Pharmaceuticals, Inc. (RAFA) Announces Engagement of QualityStocks Investor Relations Services
Rafarma Pharmaceuticals Registers CEFTRIAXONE Under International Label
Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.19, up 25.83%, on 13,900 volume with 5 trades. The stock’s average daily volume over the past 60 days is 23,127, and its 52-week low/high is $0.1163/$1.82.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise Investments Reports Financial Results for First Quarter 2013
GlobalWise Enters Into New Channel Sales Partnership With Muratec America
GlobalWise Investments Announces Results for Fiscal Year 2012
The Aristocrat Group Corp. (ASCC)
The QualityStocks Daily Newsletter would like to spotlight The Aristocrat Group Corp. (ASCC). Today, The Aristocrat Group Corp. closed trading at $0.33, up 10.00%, on 172,573 volume with 20 trades. The stock’s average daily volume over the past 60 days is 105,078, and its 52-week low/high is $0.25/$1.25.
The Aristocrat Group Corp. (ASCC) is a brand management company focused on providing premiere luxury goods through continual innovation. Luxuria Brands, a subsidiary of The Aristocrat Group, has been established to identify and promote unique brands that have mass market appeal across a diverse demographic.
Luxuria Brands is primarily concentrated on distilled spirits industries, with an initial focus on Vodka branding and marketing. The worldwide distilled spirits market is currently worth about $263 billion. In the U.S. alone, Vodka sales between 2004 and 2009 grew 25% from 13.9 million cases to 58.4 million cases. The clear liquor now accounts for almost a third of all distilled spirits consumed and continues to rise in popularity.
The Aristocrat Group is also pursuing opportunities in the women’s lifestyle industry. The World Bank recently estimated that the earning power of women will reach $18 trillion by 2014, which is twice the estimated 2014 GDP of China and India combined. The Aristocrat Group is working to bring fresh, innovative prenatal and postpartum solutions to women who are looking for a more comprehensive approach to wellness.
The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. The company aims to take a leadership position in multiple growing markets that offer opportunities for partnership, sponsorship, and brand awareness activities. The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. Disclaimer
The Aristocrat Group Corp. Company Blog
The Aristocrat Group Corp. News:
ASCC’s New Vodka Expected to Meet Federal Requirements for ‘Gluten-Free’ Labeling
ASCC Teams up With Experienced Ad Firm to Drive Sales of Debut Vodka
ASCC Details Its Keys to Profitability in $5.5 Billion U.S. Vodka Market
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.30, up 3.45%, on 88,600 volume with 28 trades. The stock’s average daily volume over the past 60 days is 115,892, and its 52-week low/high is $0.161/$0.45.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation to Present at Two Upcoming Investor Conferences
ISCO Announces First Quarter 2013 Financial Results and Provides Business Update
International Stem Cell Corporation to Host Q1 2013 Financial Results Conference Call at 11:00 a.m. ET on Tuesday, May 14, 2013
Rafarma Pharmaceuticals is one of Russia’s newest and most promising pharmaceutical companies. A company whose development and growth is being actively encouraged by the government, in a move to lessen Russian dependence upon western pharmaceutical companies for widely used pharmaceuticals, Rafarma is currently specializing in the production of generic antibiotics, but has a growing pipeline of other drugs, including proprietary products already approved.
The company expects significant near-term results with its line of current and researched pharmaceuticals, including the following group of antibiotics.
• Benzalconium Fluoride – Open randomized study of the efficacy and safety of the drug “benzalkonium fluoride, topical solution 1 %” in patients with purulent-infected wounds.
• Benzomet – Open randomized study of the efficacy and safety of the drug “benzomet, vaginal suppositories” in patients with urogenital trichomoniasis.
• Benzolete – Open randomized study of the efficacy and safety of “benzolete, lozenges for resorption – 1 mg” in patients with inflammatory diseases of the mucous membranes of the oral cavity and pharynx.
• Benzoteks – Open randomized study comparative study of the efficacy and safety of the drug “benzoteks, vaginal suppositories with benzalkonium FLUORIDE – 18.9 mg” in patients with bacterial vaginosis.
Below is a list of various Rafarma products, in order of expected sales (USD) by 2014. Rafarma also deals with many drugs for contracted production.
• Pasco ($5,910,186)
• Amoxicillin+clav-k ($5,700,175)
• Azithromycin ($4,782,939)
• Clopidogrel ($4,088,210)
• Betahistine ($3,795,417)
• Glibenclamide+Metformin ($3,463,513)
• Metoprolol ($2,911,183)
• Metformin ($2,865,075)
• Bisoprolol ($2,418,957)
• Levofloxacin ($2,338,084)
• Glycine ($2,274,287)
• Vancomycin ($1,467,387)
• Quetiapine ($1,354,435)
• Cefotaxime ($1,193,041)
• Clarithromycin ($1,015,775)
• Ciprofloxacin ($839,219)
• Ibuprofen ($749,831)
• Glimepiride ($719,375)
• Norfloxacin ($710,766)
• Glibenclamide ($653,162)
• Doxycycline ($548,019)
• Risperidone ($486,959)
• Cefuroxime ($399,884)
• Ofloxacin ($362,786)
• Amoxicillin + sulbactam ($196,700)
• Capreomycin ($192,502)
• Lomefloksatsin ($59,309)
For more information, visit www.rafarma.us
Mobile devices have become an indispensable personalized link to the outside world in ways that the developers of the original location-locked telephone never could have imagined. Increasingly we take our world with us, demanding answers and reach wherever we are, at any time of the day or night. It’s a tall order when you consider the volume and complexity of every person’s unique information flow.
Over half of online activity now occurs through mobile devices, especially impressive when you consider the fact that Google alone, a focal point for online activity, gets over a billion visits every day. It translates into billions of mobile devices serving the human global population, and a market of staggering size and scope led by Samsung, Nokia, and Apple.
Although every new iteration of mobile device brings with it new capabilities and perceptions, which can cause swings in the mobile marketplace, the companies that provide accessories to such devices are in a smart position. Changes in devices are often internal, leaving associated accessories still applicable. Even if the changes affect accessory use, it simply represents a new opportunity for accessory producers to modify their product and sell to a new market.
DoMark International, through its subsidiary SolaWerks, is aggressively tapping the mobile device accessory market, with technology-based products that fit an important need and are differentiated in the marketplace. In particular, the company’s new IR Charger Case, with innovative patent pending INFRASOL technology that provides both infrared and solar charging features for Apple iPhone and Samsung Galaxy devices, is also backed up with two high density lithium batteries providing an additional doubling of battery life.
The scheduled launch for the new product is in August of this year, and is aimed at the millions of Apple iPhone and Samsung product users around the world. DoMark CEO, Andy Ritchie, stated, “There is nothing in the market like this product, and we wanted to make sure we were completely ready to handle a large global role out and huge demand.”
For more information, visit www.DoMarkIntl.com
Trio Resources, an exploration and small-scale processing company reported financial results for the second quarter ended March 31, 2013, marking the first revenues recorded since the company’s inception in May, 2012. The company also recapped its first-quarter achievements, including its five-year off-take agreement with United Commodity AG.
“During the first quarter, we continued to distinguish ourselves from other junior mining companies by executing on our strategy to monetize our significant stockpiles of mineralized materials and securing a five year off-take agreement with United Commodity AG, one of the world’s leading processors of precious metals,” Duncan Reid, CEO of Trio Resources stated in the press release. “By closing the more than $30 million United Commodity deal, we not only reached a major milestone by generating our first revenues as a public company, but we secured a consistent and significant revenue stream that will enable us to fund operations and future growth opportunities for years to come.”
Trio reported a second-quarter net loss of $489,965, compared to a net loss of $686,801 from the first quarter of 2013. Comprehensive net loss was $464,214, or $0.0014 per basic and diluted share, as compared to a net loss of $699,682, or $0.002 per basic and diluted share, for the first quarter of 2013.
The company achieved revenues of $166,299, the first revenues the company recorded since it was established May 16, 2012.
Operating expenses decreased by 4 percent to $656,264 from operating expenses of $686,801 from the previous quarter of 2013.
“Overall, we are incredibly pleased with the progress we are making and we believe Trio Resources is well-positioned for continued success,” Reid stated. “Going forward, based on our agreement with United Commodity and the strong recovery rates we are seeing with each shipment of our mineralized material, we are confident we will achieve quarterly revenues in the range of $1 to $1.5 million.”
For more information visit www.trioresources.com
eMagin, a leader in OLED microdisplay technology, OLED microdisplay manufacturing know-how, and mobile display systems, announced yesterday that it has developed the world’s brightest family of super bright, energy efficient, and full color organic light emitting diode (OLED) microdisplays, called the Color OLED-XLS™.
At 1000 nits of luminance, the Color OLED-XLS™ blows away the industry standard for brightness four times over. This new display is fully compatible with eMargin’s entire VGA, SVGA, SXGA, and WUXGA, and only requires half of the power of the company’s current color displays at the same brightness. This breakthrough display technology enables a much broader range of optical solutions for augmented vision/reality products used in simulation and training devices, or any other head-mounted display application. Additionally, this technology is perfectly suited for medical, maintenance, and process-control “see-through” data glasses and safety goggles.
eMagin’s initial showcase of its breakthrough Color OLED-XLS will be at the Vancouver Convention Center next week for the Society for Information Display, booth #1029. Fully qualified production units are scheduled for release by the fourth quarter 2013, and engineering samples are available immediately.
“Our clients have been asking us to push the known limits in order to create more versatile color microdisplays that are both visible in bright environments and power efficient. We have met and surpassed both requirements with the development of the Color OLED-XLS,” said Andrew G. Sculley, president and CEO of eMagin Corporation. “This technology will enable indoor and outdoor augmented reality headsets for commercial, military and industrial use. We are well on the way to OLED microdisplays that can be even brighter for aircraft heads-up displays and consumer data glasses.”
For further information, please visit www.emagin.com
Today's Top 3
The Motley Fool
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) Announces 2013 Annual Meeting of Stockholders
- Consorteum Holdings, Inc. (CSRH) Enters Partnership Agreement With KO Entertainment, Inc.
- Cardium Therapeutics, Inc. (CXM) Announces Generx Publication In Molecular Therapy
- DoMark International, Inc. (DOMK) Announces Move to Protect Shareholders by Cancelling 50k Preferred Shares, 5.74M Common A Shares
- GNCC Capital, Inc. (GNCP) to Complete Acquisition
- GlobalWise Investments, Inc. (GWIV) Reports Financial Results for First Quarter 2013
- International Stem Cell Corp. (ISCO) to Present at Two Upcoming Investor Conferences
- Loans4Less.com, Inc. (LFLS) CEOCFO Magazine Interview Highlights Solid Market Position
- Low Carbon Technologies International, Inc. (LWCTF) Plans to Announce 6 Month YTD Financials
- Rafarma Pharmaceuticals, Inc. (RAFA) Announces Engagement of QualityStocks Investor Relations Services
- Rainbow Coral Corp. (RBCC) Partner n3D Signs U.S. Distribution Agreement
- The Aristocrat Group Corp. (ASCC) New Vodka Expected to Meet Federal Requirements for ‘Gluten-Free’ Labeling
- The Guitammer Company Inc. (GTMM) Announces First Quarter 2013 Results
- VentriPoint Diagnostics Ltd. (VPTDF) Announces Private Placements
- Viaspace, Inc. (VSPC) Giant King Grass to Biogas for Electricity Paper Presented at International Biomass Conference
- VistaGen Therapeutics, Inc. (VSTA) and Duke University Publish Results on Production of Functional 3D Human Heart Tissue